2016
DOI: 10.5152/ucd.2016.3375
|View full text |Cite
|
Sign up to set email alerts
|

Evolution of management in peritoneal surface malignancies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 64 publications
(59 reference statements)
0
3
0
Order By: Relevance
“…The indication for pulmonary metastasectomy has been based on Thomford's criteria (1) for a long time, but recently, it was increasingly extended to patients with multiple lesions, bilateral lesions, and solitary liver metastasis. Furthermore, the development of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy appears to contribute to better prospects of cure for patients with peritoneal dissemination (2). In this study, we included survival in patients who had been or were foreseen to be treated for peritoneal dissemination.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The indication for pulmonary metastasectomy has been based on Thomford's criteria (1) for a long time, but recently, it was increasingly extended to patients with multiple lesions, bilateral lesions, and solitary liver metastasis. Furthermore, the development of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy appears to contribute to better prospects of cure for patients with peritoneal dissemination (2). In this study, we included survival in patients who had been or were foreseen to be treated for peritoneal dissemination.…”
Section: Discussionmentioning
confidence: 99%
“…Peritoneal dissemination originating from gastrointestinal tract organs, pseudomyxoma peritonei, or ovarian cancer has for long been considered as a lethal disease with poor prognosis. Recently, however, new treatment methods have emerged, and nowadays even cure can be achieved with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in these patients (2). Consequently, we also need to analyze the prognosis of patients with peritoneal dissemination controlled by the treatments.…”
Section: Introductionmentioning
confidence: 99%
“…The concept of IPC is still evolving (107). Understanding the molecular mechanisms in gastric cancer, developing new drugs that are more efficient in systemic and IPC as well as the targeted immunotherapy agents, and achieving acceptable perioperative morbidity, will possibly lead to better survival outcomes.…”
Section: Novel Approachesmentioning
confidence: 99%